Results 81 to 90 of about 8,927 (183)

Periodontitis and rheumatoid arthritis—Global efforts to untangle two complex diseases

Periodontology 2000, EarlyView.
Abstract Understanding the impact of oral health on rheumatoid arthritis (RA) will inform how best to manage patients with both periodontitis and RA. This review seeks to provide an update on interventional and mechanistic investigations, including a brief summary of European Research programs investigating the link between periodontitis and RA. Recent
Isabel Lopez‐Oliva, Jennifer Malcolm, Shauna Culshaw   +2 more
wiley   +1 more source

A Matching-Adjusted Indirect Comparison of Guselkumab and Secukinumab in Patients with Psoriatic Arthritis Over 52 Weeks

Rheumatology and Therapy
Introduction Studies evaluating the long-term comparative efficacy between biologic therapies for psoriatic arthritis (PsA) are scarce. Two biologic therapies, guselkumab and secukinumab, were evaluated up to 52 weeks in a mixed patient population ...
Suzy van Sanden, Agata Schubert, Barkha P. Patel, Miriam Zimmermann, Fareen Hassan   +4 more
doaj   +1 more source

Sex Differences in Medication Discontinuation in Axial Spondyloarthritis

Arthritis Care &Research, Volume 78, Issue 7, Page 914-924, July 2026.
Objective We examined sex differences in medication discontinuation among patients with axial spondyloarthritis (axSpA) initiating tumor necrosis factor inhibitors (TNFi), interleukin‐17 inhibitors (IL‐17i), or JAK inhibitors (JAKi). Methods Using data from the Rheumatology Informatics System for Effectiveness (RISE) Registry (2003–2025), we assessed ...
Rachael Stovall, Cinthia Blat, Eric Roberts, Jean W. Liew, Katherine Wysham, Namrata Singh, Janna Friedly, Lianne S. Gensler, Gabriela Schmajuk, Jinoos Yazdany   +9 more
wiley   +1 more source

Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy

Dermatology Practical & Conceptual
Introduction: Risankizumab and secukinumab are effective treatment options for patients with moderate to severe psoriasis. Objective: We sought to estimate the efficacy and the cost per responder of risankizumab and secukinumab by comparing these two ...
Federico Pirro, Giacomo Caldarola, Nicoletta Bernardini, Maria Grazia Celeste, Annunziata Dattola, Eleonora De Luca, Marco Galluzzo, Domenico Giordano, Chiara Izzi, Giulia Maretti , Lorenzo Marcelli, Roberto Ravasio, Antonio Giovanni Richetta, Nevena Skroza, Marina Talamonti, Arianna Zangrilli, Luca Bianchi, Giovanni Pellacani, Severino Persechino, Concetta Potenza, Ketty Peris, Clara De Simone   +21 more
doaj   +1 more source

Pharmacokinetic‐pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real‐world data

British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 2136-2146, July 2026.
Abstract Aim Risankizumab is a high‐cost biologic treatment for chronic plaque psoriasis, an immune‐mediated inflammatory disease presenting with painful red scaly skin lesions. Inter‐individual heterogeneity in treatment response may be better addressed with personalised rather than fixed dosing. We sought to develop a pharmacokinetic/pharmacodynamic (
Charlotte M. Thomas, Jessica Ruoheng Wei, David Baudry, Zehra Arkir, Bola Coker, Tejus Dasandi, Kingsley Powell, Monica Arenas‐Hernandez, Jenny Leung, Krystal Rawstron, Chioma Nwaogu, Richard Woolf, Andrew E. Pink, Jonathan Barker, Joseph F. Standing, Catherine H. Smith, Satveer K. Mahil   +16 more
wiley   +1 more source

Patient‐ and Clinician‐Related Factors Associated With the Reduction in Opioid Use Among Adults With Chronic Non‐Cancer Pain: A Systematic Review

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 66-80, July 2026.
Despite known risks, opioids are widely used for chronic non‐cancer pain (CNCP). Clinical guidelines now recommend deprescribing, but factors predicting success are poorly understood. This systematic review aimed to identify clinician and patient factors associated with attaining successful opioid dose reduction or discontinuation in adults with CNCP ...
Alessandra C. Marcelo, Sarah N. Hilmer, David J. Hunter, Stephanie Mathieson, Riyaas Mohamed, Leo Li, Natalie Fung, Anthony Yue, Manuela L. Ferreira   +8 more
wiley   +1 more source

Interplay between COVID-19 and Secukinumab treatment in Spondylarthritis patients during the omicron surge: a retrospective cohort study

Autoimmunity
The objective of this retrospective cohort study was to assess the relationship between Corona Disease 2019 (COVID-19) and Secukinumab treatment in patients with Spondylarthritis (SpA) in China during the omicron surge. Researchers retrieved 1018 medical
Tong Wu, Yanhong Li, Deying Huang, Yinlan Wu, Xiuping Liang, Lu Cheng, Zehui Liao, Fang Xu, Ye Chen, Jing Zhao, Zijing Xia, Chunyu Tan, Yi Liu, Martin Herrmann   +13 more
doaj   +1 more source

Financial Toxicity Associated with Biological Medicines: A Scoping Review

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 81-93, July 2026.
Financial toxicity, defined as the economic burden experienced by patients due to medication and other healthcare costs and their consequences, such as material, psychosocial and behavioral effects, represents a significant concern for individuals receiving biological medicines.
Laura Sara Maria Saarukka, Kamilla Yamileva, Kari Linden, Anniina Simonen, Anna‐Riia Holmström   +4 more
wiley   +1 more source

2024 Update of the Asia‐Pacific League of Associations for Rheumatology (APLAR) Recommendations for Rheumatoid Arthritis Management

International Journal of Rheumatic Diseases, Volume 29, Issue 7, July 2026.
ABSTRACT Aim To update the Asia‐Pacific League of Associations for Rheumatology (APLAR) treatment recommendations for rheumatoid arthritis (RA) by incorporating new evidence and reassessing the validity of previous guidance: Methods A literature search for relevant publications from January 2018 to August 2023 was conducted, supplemented by earlier ...
Kunihiro Yamaoka, Zhanguo Li, Khin Thin Zar Myo Aung, Paul Bird, Manisha Bhochhibhoya, Minhaj Rahim Choudhury, Debashish Danda, Tsolmon Darisuren, Rudy Hidayat, Nguyen Van Hung, Yuko Kaneko, Wanruchada Katchamart, Manjari Lahiri, Chin Teck Ng, Babur Salim, Keshav Raj Sigdel, Shereen Ch'ng Suyin, Tsutomu Takeuchi, Galymzhan Togizbayev, Evan Vista, Sandini Wijeweera, Chuanhui Xu, Chak Sing Lau   +22 more
wiley   +1 more source

Specialty‐Based Disparities in Biologic Use and Retention in Psoriatic Arthritis: A Nationwide Korean Claims Analysis

International Journal of Rheumatic Diseases, Volume 29, Issue 7, July 2026.
ABSTRACT Aim Biologic agents play a pivotal role in controlling both articular and cutaneous manifestations of psoriatic arthritis (PsA). Although international guidelines emphasize the appropriate use of biologics, Korea lacks standardized treatment protocols tailored for PsA across specialties.
Bon San Koo, Ye‐Jee Kim, Yeo‐Jin Lee, Yong‐Gil Kim, Tae‐Hwan Kim   +4 more
wiley   +1 more source